Priority review your cooked



Their PDUFA is October. They will have a soft launch right after approval then full launch by Jan. Simultaneously they will petition FDA to pull non abuse deterrent forms from the market. Even if not successful immediately, which they will be, prescribers will have no reason to go out on a limb for Zohydro when they have Purdue's product to safely prescribe. Sorry, just the facts.
 
Their PDUFA is October. They will have a soft launch right after approval then full launch by Jan. Simultaneously they will petition FDA to pull non abuse deterrent forms from the market. Even if not successful immediately, which they will be, prescribers will have no reason to go out on a limb for Zohydro when they have Purdue's product to safely prescribe. Sorry, just the facts.

They'll never pull it together that fast, quit being pessimistic, approval won't be till 2015 at the earliest.
 
Their PDUFA is October. They will have a soft launch right after approval then full launch by Jan. Simultaneously they will petition FDA to pull non abuse deterrent forms from the market. Even if not successful immediately, which they will be, prescribers will have no reason to go out on a limb for Zohydro when they have Purdue's product to safely prescribe. Sorry, just the facts.


You all knew it was a huge risk when you accepted the job and you bet your livelihood on it anyway. Never mortgage your house on a bet, because you could lose. So sorry, but you knew it was iffy at best. Start looking and good luck.
 
Please review the sequence of events in spring 2013 - Purdue successful with petition to FDA to remove non abuse deterrent forms of oxy from the market. Very logical next step upon their approval in October, remove Zohydro. Perhaps Zogenix can stay on the market while waiting for their next generation product, but not many (if any) physicians will have a reason to prescribe. Zogenix will continue to reduce the company headcount as directed by the Board. Jobs will be scarce. Advise moving on ASAP.
 
Please review the sequence of events in spring 2013 - Purdue successful with petition to FDA to remove non abuse deterrent forms of oxy from the market. Very logical next step upon their approval in October, remove Zohydro. Perhaps Zogenix can stay on the market while waiting for their next generation product, but not many (if any) physicians will have a reason to prescribe. Zogenix will continue to reduce the company headcount as directed by the Board. Jobs will be scarce. Advise moving on ASAP.

If FDA didn't can Zohydro after the AC vote, there is no way in hell they will remove it from the market. To do so, they would have to remove Exalgo, generic oxymorphone, and immediate release oxycodone (30 mg; Roxicodone).

They will sit on the sidelines until ADT Zohydro comes out.
 
I'm sure you are right which is why the stock is doing so well.
 
If FDA didn't can Zohydro after the AC vote, there is no way in hell they will remove it from the market. To do so, they would have to remove Exalgo, generic oxymorphone, and immediate release oxycodone (30 mg; Roxicodone).

They will sit on the sidelines until ADT Zohydro comes out.

Exalgo has ADT in it . Also it just went generic. Keep drinking the koolaid!
 
Exalgo has ADT in it . Also it just went generic. Keep drinking the koolaid!

Exalgo probably does have some ADT but they didn't file with it and it's not in their label.

FDA will run the clock out on Zohydro. Removing an approved opioid from the market means they have to justify leaving all the others on the market, when there's no scientific basis for singling out Zohydro.
 
Exalgo probably does have some ADT but they didn't file with it and it's not in their label.

FDA will run the clock out on Zohydro. Removing an approved opioid from the market means they have to justify leaving all the others on the market, when there's no scientific basis for singling out Zohydro.

If your curious about the ADT in Exalgo just ask your targets that write it. They all have seen the physical properties it has and human abuse liability studies. Just because it's not on the label doesn't mean it isn't there. You see in today Chronic Pain market docs actually do care about improving the safety of these drugs. That's why all of you get to look for new jobs soon!
 
If your curious about the ADT in Exalgo just ask your targets that write it. They all have seen the physical properties it has and human abuse liability studies. Just because it's not on the label doesn't mean it isn't there. You see in today Chronic Pain market docs actually do care about improving the safety of these drugs. That's why all of you get to look for new jobs soon!

Why is Exalgo only doing $100 mil per year if it's so whiz bang? And the trend is down.

It's feckin' hydromorphone for god's sake. Not mother's milk.
 
Why is Exalgo only doing $100 mil per year if it's so whiz bang? And the trend is down.

It's feckin' hydromorphone for god's sake. Not mother's milk.

More like $230 mil. It went generic that's why the trend is down bozo. Your so smart I bet you think this thread is about you! here is the link to back it up.
http://www.actavis.com/news/news/thomson-reuters/actavis-receives-final-approval-for-generic-versio

Exalgo, OxyContin, Opana Er, Nucynta Er and a few more: They all have something in common - Abuse Detterent Technology. Oh yeah one other thing success in the market.

Get with the program geniuse!
 
Net sales in the Specialty Pharmaceuticals segment for the first quarter of fiscal 2014 were $309.5 million, an increase of 18.9%, compared with $260.2 million in the prior-year period. Operational growth was 19.1%. Net sales in Brands were $59.6 million, compared with $46.6 million last year, led by net sales from EXALGO(R) (hydromorphone HCl) Extended-Release Tablets, CII. Net sales in Generics and Active Pharmaceutical Ingredients (API) were $249.9 million, compared with $213.6 million last year, primarily driven by net sales from Methylphenidate HCl Extended-Release Tablets, USP CII (Methylphenidate ER) and the net benefit from pricing actions on certain specialty generics products.

Where are you getting $230 million?. Actavis generic approved but not available yet (or only recently)?

Can't explain 2013 results for first 2 quarters of 2014.
 


Write your reply...